RxDoctor Payments DataLook up a doctor →

Iltefat Hamzavi, MD

Procedural Dermatology · Canton, MINPI 1538117866

Payments from drug & device makers

$1,328,151in general payments, 2019–2025

Across 649 payments — averaging $2046.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$530K
  • AbbVie$263K
  • Incyte Corporation$221K
  • Avita Medical Americas, LLC$139K
  • UCB, Inc.$48K
  • Teva Pharmaceuticals USA, Inc.$41K
  • plus $86K from 32 others
$40,650in research payments, 2019–2025

Across 28 payments — averaging $1451.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$35K
  • Novartis Pharma AG$5K

What the payments were for

  • Consulting fees$361,32179%
  • Speaking & faculty fees$67,19615%
  • Travel & lodging$21,6655%
  • Food & beverage$7,7982%
  • Education$1820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$206,086
Medicare patients
797
Services billed
3,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HumiraAdalimumab14$99,343
Dupixent PenDupilumab14$54,483
OpzeluraRuxolitinib Phosphate18$35,115
Tacrolimus25$3,359
Fluorouracil26$1,643
Tranexamic Acid12$1,370
Ketoconazole39$886
Clobetasol Propionate24$559
Fluocinolone Acetonide13$439
Fluocinonide17$396
Triamcinolone Acetonide45$327
Spironolactone14$231
MethotrexateMethotrexate Sodium23$226
Dexamethasone13$220
Hydrocortisone20$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira$263,150$99,34314 claims
Incyte CorporationOpzelura$220,650$35,11518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few procedural dermatology providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other procedural dermatology in Canton

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →